About
Intelligence at the speed of discovery
Compressing the timeline from hypothesis to approved therapy.
8
Core Engines
24/7
Autonomous Ops
3
Continents
2026
Founded
Mission
“Every day of delay is a day patients wait. Every dollar wasted on inefficient tools is diverted from discovery.”
The clinical trial industry runs on infrastructure built decades ago. TrialDataX.AI replaces disconnected point solutions with a unified intelligence layer.
Origin
Built from research. Designed for production.
Born from doctoral AI research at George Washington University. Every model, pipeline, and engine built from zero. Vertically integrated — no third-party assemblies.
Intellectual Property
Patent-pending innovation
USPTO provisional filings protecting 8 core innovations.
Milestones
2023
Research Genesis
Doctoral AI research at GWU SEAS — temporal deep learning for trial optimization.
2024
Platform Architecture
Core engines built from scratch. No third-party APIs.
2025
Production Launch
8 AI engines, adaptive analytics, and CTDM marketplace go live.
2026
Incorporation
Delaware C-Corp. 23 Ventures joins. Engineering across three continents.
Company
TrialDataX.AI Inc.
Delaware C-Corp, formed April 2026. Backed by GWU SEAS AI research and 23 Ventures. Leadership includes Richard C.E. Morgan (co-founder of Celgene, 40+ life science companies) as Executive Chairman. Team from Google, Columbia, LBS, and MIT.